ASX - Delayed Quote AUD

Recce Pharmaceuticals Ltd (RCE.AX)

0.2900

-0.0100

(-3.33%)

At close: 4:10:17 PM GMT+10

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

A$5.0 million commitment received from Australian-based private investorA$10.8 million Entitlement Offer at the same offer price as the placementFunds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026Directors intend to take up entitlements in part or in full in the Entitlement Offer SYDNEY, April 10, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), a leading developer of a new class of synthetic

GlobeNewswire yesterday

RECEF
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives

SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was granted a Family 4 patent by the Japan Patent Office for its anti-infectives, with expiry in 2041. “We are encouraged by the Japan Patent Office’s formal recognition of Recce’s new class of anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Global patent protect

GlobeNewswire last month

RECEF
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

Phase II trial assessed the efficacy and safety of RECCE® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections (DFI)Study objectives exceeded, with a 93% primary efficacy endpoint achieved for R327G over 14 days of treatmentData confirms the approach for the approved registrational Phase 3 DFI study in Indonesia, where efficacy can be confirmed earlier in the trial through interim analysis and read-out expecte

GlobeNewswire last month

RECEF
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data analysis expected in Q1 2025Additional Australian regulatory trials to be initiated in H1 2025 SYDNEY, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced the dosing completion of 30 patients in a Phase II

GlobeNewswire 2 months ago

RECEF
Recce Pharmaceuticals Receives Approval from Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections

Registrational Phase 3 trial for diabetic foot infections to be conducted across Indonesia, one of the world's largest diabetes patient populationsAwarded expedited regulatory review status in Indonesia to fast-track progression of Phase 3 trial, bringing forward commercial opportunities in ASEAN region SYDNEY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced

GlobeNewswire 3 months ago

RECEF
Investors in Recce Pharmaceuticals (ASX:RCE) have seen notable returns of 68% over the past five years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Simply Wall St. 4 months ago

RECEF
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office has formally granted Recce a family three patent for its anti-infectives, with expiry in 2037. “We are thrilled by the Australian Patent Office’s formal recognition of the ground-breaking potential of Recce’s New Class of Anti-Infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceut

GlobeNewswire 4 months ago

RECEF
Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections

Human Research Ethics Committee approval received for registrational Phase 3 trial for RECCE® 327 topical gel in patients with diabetic foot infectionsRegistrational Phase 3 clinical trial for diabetic foot infections to be conducted across Indonesia, one of the world's largest diabetes patient populationsData read-out and regulatory submission expected in late 2025 with potential approval and commercial launch in H1 2026Bilateral initiative supported by Australian and Indonesian governments wit

GlobeNewswire 4 months ago

RECEF
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Trial reaches dosing milestone, with 20 of the 30 total patients dosedAll patients dosed met the primary endpoints of the study, either a cure or notable improvement following treatment with RECCE® 327 topical gel (R327G)Patient dosing on track to be completed by the end of 2024 SYDNEY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced it is nearing completion of

GlobeNewswire 5 months ago

RECEF
Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial

RECCE® 327 Topical Gel (R327G) was demonstrated to be safe and well-tolerated in patients – R327G demonstrating highly encouraging efficacy results as determined by non-Data Safety Monitoring BoardAll patients completing treatment with R327G met the primary endpoint of complete cure or improvement, seen as early as 7 daysNo Serious Adverse Events noted in patients - recommendation for clinical trial to continue, reflecting promising potential of R327G as a safe and effective treatment for acute

GlobeNewswire 5 months ago

RECEF
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Phase II trial assessing the efficacy of RECCE® 327 topical gel (R327G) against acute bacterial skin and skin structure infectionsR327G demonstrating promising antibacterial effect across a broad range of human infectionsClinical study review board on track for mid-October, with interim results to followTrial study locations expand across New South Wales (NSW) and Victoria, broadening access to this potentially novel approach SYDNEY, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd.,

GlobeNewswire 5 months ago

RECEF
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan

A$4.4 million of valid applications received for the Share Purchase PlanIn conjunction with recently completed A$8.0 million institutional placement, total amount raised is A$12.4 millionProceeds will be used to advance clinical trials for intravenous use of R327, topical applications of R327G, including Phase III clinical activities in Indonesia, and IND-enabling activitiesPro forma cash position of A$19.8 million SYDNEY, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FS

GlobeNewswire 8 months ago

RECEF
Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel

Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military settingR327G to be evaluated as a potential replacement for traditional antimicrobial dressings and topicals used in the military setting SYDNEY, July 16, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today anno

GlobeNewswire 8 months ago

RECEF
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii

RECCE® 327 (R327) demonstrated significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) demonstrating 99.99999% log reduction (>7.5 log reduction) in adult human epidermal ‘skin’ cellsA. baumannii is most commonly responsible for urinary tract infections, ventilator-associated pneumonia, central line-associated bloodstream infections, persistent wound infections and meningitisThe data supports upcoming Phase II Acute Bacterial Skin and Skin Structure Infection

GlobeNewswire 8 months ago

RECEF
Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo serious adverse events and clinically significant changes observed, reinforcing safety profile of R327The study determined an optimal dosing regimen for R327 intravenously, showing rapid onset and sustained impact on Escherichia coli via an ATP mechanism in the urine of dosed participantsRecce on track to initiate Phase II trial of R327 in patients with urinary

GlobeNewswire 9 months ago

RECEF
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval received for Phase II trial of R327 for acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot and wound infectionsNew site initiation commenced with first patients to be dosed in Q3 2024This trial builds upon clinical results of R327 tested against burn wound and diabetic foot infections SYDNEY, Australia, June 25, 2024

GlobeNewswire 9 months ago

RECEF
Those who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 170%

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...

Simply Wall St. 9 months ago

RECEF
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening and resistant bacteriaSYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced its primary anti-infective candidate, RECCE® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agent

GlobeNewswire 9 months ago

RECEF
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial

Six additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in this trialSYDNEY, June 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed dosing an additional cohort in its Phase I/II UTI/Urosepsis trial, evaluating RECCE® 327 (R327) at fast infusion rates. "We have successfully reached a new milestone

GlobeNewswire 9 months ago

RECEF
Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trialRECCE® 327 (R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levelsMinimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, May 17, 2024 (G

GlobeNewswire 10 months ago

RECEF

Performance Overview

Return	RCE.AX	S&P/ASX 200 [XJO] (^AXJO)
YTD	-40.21%	-6.28%
1-Year	-38.95%	-2.14%
3-Year	-68.84%	+2.15%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Recce Pharmaceuticals Ltd (RCE.AX)

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Receives Approval from Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections

Investors in Recce Pharmaceuticals (ASX:RCE) have seen notable returns of 68% over the past five years

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial

Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan

Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Those who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 170%

Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial

Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Performance Overview